CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimoto's thyroiditis

Histopathology

Volumn 55, Issue 6, 2009, Pages 683-686

  Anderson, Catriona E ^a   Graham, Catriona ^b   Herriot, Michael M ^a   Kamel, Hassan M ^a   Salter, Donald M ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

CD98; Hashimoto's thyroiditis; Papillary carcinoma; Thyroid

Indexed keywords

CD98 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; FOLLICULAR CARCINOMA; GOITER; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY FOLLICLE CELL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ANTIGENS, CD98; CARCINOMA, PAPILLARY; DOWN-REGULATION; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; THYROID GLAND; THYROID NEOPLASMS;

EID: 70849088111     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03438.x     Document Type: Article

References (20)

1. Nakamura E, Sato M, Yang H et al. 4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer. J. Biol. Chem. 1999 274 3009 3016.
2. Haynes BF, Hemler ME, Mann DL et al. Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J. Immunol. 1981 126 1409 1414.
3. Yan Y, Vasudevan S, Nguyen HT, Merlin D. Intestinal epithelial CD98: an oligomeric and multifunctional protein. Biochim. Biophys. Acta 2008 1780 1087 1092.
4. Rossier G, Meier C, Bauch C et al. LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J. Biol. Chem. 1999 274 34948 34954.
5. Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997 390 81 85.
6. Henderson NC, Collis EA, Mackinnon AC et al. CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation. J. Biol. Chem. 2004 279 54731 54741.
7. Feral CC, Nishiya N, Fenczik CA, Stuhlmann H, Slepak M, Ginsberg MH. CD98hc (SLC3A2) mediates integrin signaling. Proc. Natl Acad. Sci. USA 2005 102 355 360.
8. Cai S, Bulus N, Fonseca-Siesser PM et al. CD98 modulates integrin beta1 function in polarized epithelial cells. J. Cell Sci. 2005 118 889 899.
9. Nakanishi K, Ogata S, Matsuo H et al. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2007 451 681 690.
10. Kim DK, Ahn SG, Park JC, Kanai Y, Endou H, Yoon JH. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precusor lesions. Anticancer Res. 2004 24 1671 1675.
11. Monaghan H, Williams AR. The pattern of CD98 expression is different between uterine serous papillary carcinoma and endometrioid endometrial carcinoma. Gynecol. Oncol. 2007 104 264 265.
12. Huang D, Chen W, He R, Yu F, Zhang Z, Qiu W. Different cDNA microarray patterns of gene expression reflecting changes during metastatic progression in adenoid cystic carcinoma. World J. Surg. Oncol. 2003 1 28.
13. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod. Pathol. 2008 21 (Suppl. 2 S37 S43.
14. Pelizzo MR, Merante Boschin I, Toniato A et al. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol. 2008 33 359 379.
15. Ji QH, Zhang L, Zhu YX, Huang CP. Long-term impact of initial surgical and medical therapy on young patients with papillary thyroid cancer and bilateral cervical metastases. Chin. Med. J. (Engl.) 2008 121 63 66.
16. Arif S, Blanes A, Diaz-Cano SJ. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 2002 41 357 362.
17. Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 2004 45 39 46.
18. Rhoden KJ, Unger K, Salvatore G et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J. Clin. Endocrinol. Metab. 2006 91 2414 2423.
19. Maximo V, Botelho T, Capela J et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br. J. Cancer 2005 92 1892 1898.
20. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am. J. Pathol. 2002 160 1857 1865.